[Dosage dependence of the effect of somatostatin on human splanchnic blood flow].
The effect of three different doses of somatostatin on splanchnic blood flow (SBF) and on arterial plasma insulin, glucagon and glucose was determined. 125, 250 and 500 microgram/h of somatostatin was infused during 60 minutes in 3 groups of 6 patients undergoing arterial-hepatic-venous catheterization; no patient had clinical evidence of metabolitic or hepatic disease. Continuous infusion of 125 microgram/h somatostatin was without significant effect on SBF, whereas 250 microgram/h resulted in a mean 28% reduction of SBF (p less than 0.05). Doubling the dose to 500 microgram/h affected SBF similarly (21% reduction of SBF). In contrast, administration of all three doses of somatostatin suppressed the circulating insulin and glucagon levels significantly. In a recent report somatostatin had been administered in a dose of 250 microgram/h to control gastric ulcer hemorrhage. The present studies demonstrate that this dose results in a significant reduction of SBF which cannot be further depressed by increasing the dose.
D000328:Adult; D000368:Aged; D001775:Blood Circulation / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis; D006328:Cardiac Catheterization; D004305:Dose-Response Relationship, Drug; D005260:Female; D005934:Glucagon / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D013004:Somatostatin / Q000008:administration & dosage*; D013997:Time Factors
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D005934:Glucagon
Dosisabhängigkeit der Wirkung von Somatostatin auf die splanchnische Durchblutung beim Menschen.